Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (August 2024)
33 slides from Century Therapeutics's investor presentation, Aug 8, 2024
Slide 1: Corporate Overview August 2024
Corporate Overview August 2024
Slide 2: Forward-looking statements
2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical f
Slide 3: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platform
3 Century Therapeutics: Building an industry - leading, next - generation allogeneic iPSC - derived cell therapy platform LIMITLESS POTENTIAL… PRECISION DESIGN… ENDURING IMPACT… Foundational investments in iPSC technology, genetic editing, protein engineering, and manufacturing Progressing different
Slide 4: Overview of Foundational Platform Technologies
Overview of Foundational Platform Technologies
Slide 5: Century's singular focus: best-in-class iPSC-derived cell therapies
5 Century’s singular focus: To deliver best - in - class iPSC - derived cell therapies Century platform enables the incorporation of critical features we b elieve can only be realized via iPSC - derived cell therapies Infinite replicative capacity at the iPSC stage enables potentially unlimited geno
Slide 6: Next-generation allogeneic iPSC technology platform
6 Century’s next - generation allogeneic iPSC technology platform: Versatility and unprecedented control Rapid Integration of major advances in product functionality and manufacturability iPSC iT cell iNK cell SINGLE CELL CLONING POST GENE EDITING AND CHARACTERIZATION DIFFERENTIATION Consistency Yie
Slide 7: Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells
7 Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates Multiple gene edits (KO/KI) iPSC bank Engineered iPSC Master Cell Bank (MCB) Sequential selection steps iSPC Precision Engineering CRISPR - mediated HDR (MAD 7) Advantages of Century’s Platfor
Slide 8: Allo-Evasion edits + repeat dosing = potential greater durability
8 Allo - Evasion TM edits + repeat dosing = potential greater durability Potential to drive durable responses with engineering to resist immune rejection Next - wave of allogeneic cell therapies must solve for challenge of rejection With Allo - Evasion TM engineering Without Allo - Evasion TM engine
Slide 9: Advancing our leadership in Allo-Evasion technology
9 Advancing our leadership in Allo - Evasion TM technology Continuous improvement in holistic immune protection designed to overcome major pathways of host vs. graft rejection Allo - Evasion TM 1.0 Allo - Evasion TM 3.0 Allo - Evasion TM 5.0 b 2M KO (HLA - I) CIITA KO (HLA - II) CD8 + T Cell CD4 + T
Slide 10: Foundational investments in iPSC manufacturing
10 Foundational investments in iPSC manufacturing Established in - house manufacturing Developing fit - for - purpose products • Century 53,000 ft 2 GMP facility • Designed to produce multiple immune cell types • Accelerates learnings and enables faster product iteration • Two sites (FCDI GMP manufa
Slide 11: Pipeline
Pipeline
Slide 12: Newly expanded and diversified pipeline
12 Newly expanded and diversified pipeline Product candidates spanning cell types and targets in cancer and autoimmune diseases Clinical Product iPSC Platform Targets Indications Research IND - Enabling P1 P2 P3 Collaborator Autoimmune Diseases CNTY - 101 iNK CD19 B cell - mediated Autoimmune Diseas
Slide 13: CNTY-101 Clinical Programs
CNTY - 101 Clinical Programs
Slide 14: CNTY-101: Differentiated next-gen CD19 targeted product
14 CNTY - 101: Differentiated next - gen CD19 targeted product Only cell therapy with six precision gene edits currently in the clinic Delivering on our vision to change the cell therapy treatment paradigm • Goal to improve durability, tolerability and ease of outpatient administration • Potential t
Slide 15: CNTY-101 in relapsed/refractory B-cell lymphomas
15 CNTY - 101 in relapsed/refractory B - cell lymphomas Aim : To deliver durable responses via repeat dosing facilitated by Allo - Evasion TM and extending the period of pharmacologic pressure on tumor cells R/R: Relapsed or Refractory, NHL: Non - Hodgkin Lymphoma, CAR - T: Chimeric Antigen Receptor
Slide 16: CNTY-101: ELiPSE-1 Phase 1 trial design
16 CNTY - 101: ELiPSE - 1 (NCT05336409) Phase 1 BOIN design Patients with CD19+ aggressive and high - risk indolent R/R B - NHL • Part 1 – Dose escalation – Schedule A: single dose – Schedule B: 1 dose per week x 3 weeks • Part 2 – Dose expansion BOIN: Bayesian Optimal Interval, DLT: Dose Limiting T
Slide 17: ELiPSE-1 baseline characteristics
17 1 As of 27 March 2024 data cutoff, data collection ongoing 2 One subject received allogeneic CAR - T HRFL: High - risk follicular lymphoma; DLBCL: Diffuse large B cell lymphoma ; MZL: Marginal zone lymphoma; MCL: Mantle cell lymphoma Baseline characteristics N=12 safety evaluable 1 Median age (ra
Slide 18: CNTY-101 preliminary clinical data
18 Efficacy (n=10) • 30% CRR and 40% ORR across all dose levels and histologies • 40% CRR and 60% ORR at highest studied dose levels in Schedule A Safety & Tolerability (n=12) • No treatment discontinuations due to AES ; no GvHD • CRS: Grade 1 (N=2), Grade 2 (N=2) – Hypotension (n=1) and hypoxia (n=
Slide 19: CNTY-101 emerging pharmacokinetic profile
19 cfDNA: Cell - free DNA, LD: Lymphodepletion Ramachandran, et al. 2023 ASH Annual Conference CNTY - 101 emerging pharmacokinetic profile 1 Cell - free DNA has short half - life in circulation, ranging from minutes to hours ( Khier and Lohan, Future Science 2018) • Transient detection of CNTY - 101
Slide 20: ASH 2023 case study: durable complete response
20 ASH 2023 case study: Dose level 1 patient with 6 - month durable complete response *Data cutoff date of November 13, 2023; represents data verified post data cut ^Patient subsequently progressed Ramachandran, et al. 2023 ASH Annual Conference Multiple Doses of CNTY - 101, an iPSC - Derived Alloge
Slide 21: ASH 2023 case study: early evidence of anti-lymphoma activity
21 ^Patient subsequently progressed Ramachandran, et al. 2023 ASH Annual Conference ASH 2023 case study: Early evidence of anti - lymphoma activity with durable 6 - month complete response ^ Baseline Post - initial dose (Day 28)
Slide 22: Allo-Evasion edits + repeat dosing without the need for LD
22 Allo - Evasion TM edits + repeat dosing without the need for LD With Allo - Evasion TM engineering Without Allo - Evasion TM engineering Allo - Evasion TM enables repeat dosing without the need for continued lymphodepletion Initial clinical evidence indicates no sign of allo - rejection for CNTY
Slide 23: ELiPSE-1 initial data: Key takeaways
23 ELiPSE - 1 initial data: Key takeaways Heavily pretreated and refractory patient population treated in first - in - human dose escalation trial Favorable safety profile; can be delivered in an outpatient setting Encouraging early efficacy signals at initial 3 dose levels in Schedule A Novel cfDNA
Slide 24: Key differentiators of CNTY-101 in autoimmune disease treatment
24 Key differentiators of CNTY - 101 in autoimmune disease treatment CNTY - 101: CD - 19 targeted iNK cell therapy with 6 precision gene edits including Allo - Evasion TM technology • Ph1 CALiPSO - 1 trial in B cell - mediated autoimmune diseases (Systemic Lupus Erythematosus and Lupus Nephritis) in
Slide 25: CNTY-101: Potential to drive B-cell depletion with tighter control over drug exposure
25 CNTY - 101: Potential to drive B - cell depletion with tighter control over drug exposure More potent than primary CAR - T at B - cell killing in preclinical comparison CNTY - 101 more potent than primary CAR - T cells at B - cell killing at 24 hours in preclinical comparison Isolated B cells or
Slide 26: Opportunity in systemic lupus erythematosus and lupus nephritis
26 Opportunity in systemic lupus erythematosus and lupus nephritis to improve long - term disease control 1. Tian J, et al. Ann Rheum Dis 2023;82:351 – 356 http://dx.doi.org/10.1136/ard - 2022 - 223035 2. Mackensen A, et al.. Nature Medicine 2022 28:10 (2124 - 2132) https://doi.org/10.1038/s41591 -
Slide 27: CNTY-101: CALiPSO-1 B cell-mediated autoimmune diseases Phase 1 study
27 CNTY - 101: CALiPSO - 1 (NCT06255028) B cell - mediated autoimmune diseases Phase 1 study Inclusion: • Patients with moderate to severe SLE and LN after 2+ standard immunosuppressive therapies Endpoints: • Key endpoints: Safety, Lupus activity per clinical and laboratory assessments • Translation
Slide 28: Century Therapeutics
CENTURY THERAPEUTICS
Slide 29: CNTY-102: Next generation γδ iT cell platform
29 CNTY - 102: Leveraging the next generation γδ iT cell platform designed to deliver best - in - class potential Designed to address factors that limit durability of cell therapy in B - cell malignancies • γδ iT cells have distinct properties that provide optionality in the face of different biolog
Slide 30: CNTY-107: First in class Nectin-targeted γδ iT cell therapy
30 CNTY - 107: First in class Nectin - 4 targeted γδ iT cell therapy Leveraging the power of the γδ iT cell platform for solid tumors Nectin - 4 has been validated by ADC approaches • Opportunity to address multiple Nectin - 4 positive solid tumors — Potential indications include bladder, breast, pa
Slide 31: Corporate Position & Upcoming Milestones
Corporate Position & Upcoming Milestones
Slide 32: Multiple near-term catalysts and cash resources
32 MULTIPLE NEAR - TERM CATALYSTS CASH RESOURCES Advancing next - generation iPSC - derived allogeneic NK and T cell therapy candidates for the treatment of cancer and autoimmunity Phase 1 ELiPSE - 1 trial of CNTY - 101 in B - cell malignancies • Progressing into dose expansion in 2H 2024 Phase 1 CA
Slide 33: Building an industry-leading, next-generation allogeneic iPSC-derived cell therapy platform
33 Century Therapeutics: Building an industry - leading, next - generation allogeneic iPSC - derived cell therapy platform LIMITLESS POTENTIAL… PRECISION DESIGN… ENDURING IMPACT… Foundational investments in iPSC technology, genetic editing, protein engineering, and manufacturing Progressing differen
Century Therapeutics — Investor Presentation (August 2024) on 6ix